R elying on office blood pressure (BP) measurements alone leads to a substantial misclassification of true BP status. In patients with treated arterial hypertension, misclassification can occur in >40% of patients. 1 Recently, a large Spanish registry reported that masked hypertension, that is, normal office but elevated ambulatory BP, is associated with a risk of death even greater than sustained hypertension (elevated office and elevated ambulatory BP).
R elying on office blood pressure (BP) measurements alone leads to a substantial misclassification of true BP status. In patients with treated arterial hypertension, misclassification can occur in >40% of patients. 1 Recently, a large Spanish registry reported that masked hypertension, that is, normal office but elevated ambulatory BP, is associated with a risk of death even greater than sustained hypertension (elevated office and elevated ambulatory BP). 2 White coat hypertension (elevated office but normal ambulatory BP) was not benign either, with cardiovascular and all-cause mortality similar to sustained hypertension. 2 Assessment of target organ damage (TOD) for cardiovascular risk assessment is recommended by several guidelines. Left ventricular mass (LVM) and intima-media thickness (IMT) of the common carotid artery (CCA) are established, pulse wave velocity (PWV) and central augmentation index (cAIx) novel parameters of TOD. Recent methodological improvements now allow 24-hour-ambulatory assessment of PWV and cAIx, which may further enhance their predictive ability. 3, 4 In patients with chronic kidney disease (CKD), data on BP pattern and its role for TOD are sparse. We, therefore, examined BP patterns and the association with LVM October 2018 (magnetic resonance imaging, MRI), IMT (ultrasound), 24-hour PWV, and 24-hour cAIx (Mobil-O-Graph) in 305 treated hypertensive patients with CKD enrolled into CARVIDA (Cardiovascular In-Depth Assessment in Chronic Kidney Disease), a substudy of the GCKD study (German Chronic Kidney Disease).
Methods

Study Design
The authors declare that all relevant data are provided within the article (and its online-only Data Supplement). The design of the GCKD study has been reported in detail. 5, 6 In brief, 5127 white CKD patients aged 18 to 74 years were included according to 2 inclusion criteria: an estimated glomerular filtration rate of 30 to 60 mL/ min per 1.73 m 2 or manifest proteinuria (urinary albumin/creatinine >300 mg/g or equivalent) in the presence of an estimated glomerular filtration rate >60 mL/min per 1.73 m 2 . Patients after solid organ or bone marrow transplantation, experiencing active malignancy within 24 months before screening, with a history of heart failure New York Heart Association IV, under legal attendance or not able to provide consent were excluded. The GCKD study has been approved by local ethics committees and entered into the national registry for clinical studies (DRKS 00003971).
To provide more detailed information on the cardiovascular phenotype of CKD patients, CARVIDA was performed as a GCKD substudy in Würzburg, Aachen, and Erlangen (3 out of 9 regional GCKD centers in Germany). Patients had to provide written informed consent to take part in the CARVIDA substudy. Complete office and 24-hour-ambulatory BP monitoring (ABPM) data were available in 305 patients (from a total of 322 patients). All analyses of TOD were performed without knowledge of BP group (ie, were done in blinded fashion).
Office BP Measurements and Ambulatory BP/Pulse Wave Analysis
Office BP was recorded with an oscillometric device (Infinity Gamma XL, Draeger, Lübeck, Germany) in the presence of a study nurse (attended measurements) in the supine position after 5 minutes of rest as the mean of 3 measurements. ABPM was performed with the Mobil-O-Graph PWA monitor (IEM Healthcare, Stolberg, Germany). Measurement intervals were every 15 minutes during daytime and every 30 minutes during nighttime. This monitor allows oscillometric detection of the peripheral pulse wave, from which it constructs the central pulse wave via an inbuilt algorithm (ARCSolver). PWV is calculated from the time difference between the estimated forward and reflected waves. Results of oscillometric PWV measurements are similar to intra-aortic catheter measurements. 3 cAIx is defined as the ratio of the augmentation pressure (difference between the first and the second peak of the central BP wave) to pulse pressure (difference between systolic and the diastolic pressure readings) given as a percentage. The results of cAIx are comparable to those obtained by a transfer function-based, noninvasive method (Sphygmocor system). 4 Controlled hypertension (CH) was defined as office BP <140/90 mm Hg and 24-hour BP <130/80 mm Hg; white coat uncontrolled hypertension (WCUH) as office BP ≥140/90 mm Hg and 24-hour BP <130/80 mm Hg; masked uncontrolled hypertension (MUCH) as office BP <140/90 mm Hg and 24-hour BP ≥130/80 mm Hg and sustained uncontrolled hypertension (SUCH) as office BP ≥140/90 mm Hg and 24-hour BP ≥130/80 mm Hg. Results based on BP groups defined by either daytime ambulatory BP (cutoff 135/85 mm Hg) or nighttime ambulatory BP (cutoff 120/70 mm Hg) are given in the online-only Data Supplement. Sensitivity analyses indicated that removal of the few patients not on antihypertensive therapy (n=12 in CH, n=1 in WCUH, n=7 in MUCH, and n=8 in SUCH) did not affect the results. Thus, these remained included in the BP groups as defined above. Office BP and ambulatory BP/pulse wave measurements were performed on the same day as those of LVM and IMT.
Cardiac MRI
MRI was performed on a 1.5 Tesla scanner featuring high-performance gradients (Magnetom Aera or Magnetom Avanto, Siemens AG, Erlangen, Germany). The imaging protocol contained balanced steady-state free precession cine sequences for functional and volumetric analysis. Retrospectively gated electrocardiographically triggered balanced steady-state free precession cine images were gained while patients were holding their breath in standard 4-chamber, 3-chamber, and 2-chamber long, as well as short-axis views of the entire left ventricle. The following scan parameters were used: slice thickness 8 mm, in-plane resolution 2.5 × 1.8 mm, time to echo 1.1 ms, time to repetition 42 ms, and flip angle 50°. Quantitative image data analysis was conducted using dedicated software that allows for postprocessing of cardiac MRI data (syngo.via, Siemens AG, Erlangen, Germany). LVM was measured at the end of ventricular diastole by multiplying the myocardial volume with the specific gravity of the myocardium (1.05 g/mL).
Intima-Media Thickness
The IMT of both CCA was measured in B-mode ultrasound scans using a linear 7. 
Clinical Chemistry Measurements
Plasma, serum, blood, and spot-urine were collected, processed, frozen, and shipped to a central laboratory (Synlab; Heidelberg, Germany) for measuring clinical chemistry. An isotope dilution mass spectrometry-traceable methodology was utilized to determine serum creatinine, and estimated glomerular filtration rate was estimated using the CKD-EPI (CKD-Epidemiology Collaboration) formula. 8 Bicarbonate levels were measured locally by blood gas analysis.
Statistical Analysis
All statistical analyses were performed with IBM SPSS Statistics Version 24. Graphs were generated with GraphPad Prism 6. Data were tested for normal distribution using the Shapiro-Wilk test. Data are presented as mean±SD for normally distributed variables, as median±interquartile range for non-normally distributed variables, and as percentages for categorical variables. Differences between BP groups were analyzed by 1-way ANOVA for normally distributed variables, 1-way Kruskal-Wallis test for non-normally distributed variables, and χ 2 test for categorical variables, respectively. The Bonferroni method was used for post hoc pairwise comparisons. Linear regression models were used to investigate the cross-sectional association of BP groups with parameters of subclinical TOD (LVM, IMT, 24-hour PWV, and 24-hour cAIx). The CH group was defined as the reference group for each of the regression analyses. After review of the literature, we determined that models should be adjusted for age, sex, body mass index, and diabetes mellitus status (and smoking in the case of IMT 9 ). In the graphs, the nonstandardized β-values (±95% CI intervals) are given, corresponding to the quantitative difference between each 1 of the uncontrolled BP group and CH as the reference group. Pearson or Spearmen correlation coefficients are given where appropriate.
Results
BP Pattern and Clinical Characteristics
The percentage of patients with CH was 41%. WCUH was found in 11%, MUCH in 18%, and SUCH in 30%. Table 1 shows the clinical characteristics across BP groups. Age differed between groups (P=0.001 for trend), with post hoc comparisons indicating that patients with MUCH were significantly older than patients with CH (P<0.05 by Bonferroni). We found a trend for differences with regards to body mass index, but post hoc comparisons were not significant.
Diabetes mellitus prevalence was numerically highest in patients with MUCH (P=0.01 by χ 2 ). Overall median estimated glomerular filtration rate was 49 mL/min per 1.73 m2 with no difference between BP groups. Urinary albumin excretion rate was different across groups, with post hoc comparisons indicating greater urinary albumin excretion rate in patients with MUCH versus CH, and SUCH versus CH (each P<0.05 by Bonferroni). Primary glomerulopathy (eg, IgA nephropathy), hypertensive/vascular nephropathy and diabetic nephropathy were the most common causes of renal disease. Please note that multiple causes of renal disease could be given for a patient by the referring nephrologist. Except for lipid parameters and potassium levels, no other differences in laboratory parameters were noted (Table S1 in the online-only Data Supplement). Table 2 shows the BP parameters according to group. Please note that elevated ambulatory BP was diagnosed by the 24-hour criterion (≥130 mm Hg systolic or ≥80 mm Hg diastolic). In the group of patients with MUCH (n=56), 36 (64%) patients would have additionally fulfilled the daytime criterion (≥135 mm Hg systolic or ≥85 mm Hg diastolic) and 44 (79%) would have additionally fulfilled the nighttime criterion (≥120 mm Hg systolic or ≥70 mm Hg diastolic). Thirty of the 56 patients diagnosed with MUCH based on the 24-hour criterion would have additionally fulfilled both daytime and nighttime criteria. Table 3 shows antihypertensive drug therapy across the 4 groups. Most commonly used were diuretics (overall 53%), angiotensin receptor blockers (46%), angiotensinconverting enzyme-inhibitors (45%), β-blockers (43%), and calcium channel blockers (38%). The median of the number of antihypertensive drugs was 2 with a range of 1 to 6. Calcium channel blockers were not used as often in CH as in the other BP groups. 10 Figure 1A and 1B shows the results of LVM in relation to BP pattern. In unadjusted analysis ( Figure 1A) , LVM was not significantly elevated in patients with WCUH compared with CH. Whereas LVM was increased in patients with MUCH and SUCH by 13.9 and 21.4 g, respectively. After adjustment for clinical factors, patients with WCUH, MUCH, and SUCH had greater LVM than patients with CH ( Figure 1B) .
IMT of the left CCA was slightly larger (0.70±0.15 mm in men and 0.76±0.14 in women) than IMT of the right CCA (0.65±0.14 mm in men and 0.63±0.12 mm in women; P<0.01 left versus right CCA). Figure 1C and 1D shows IMT values in relation to BP pattern, adjusted for clinical factors. IMT of the right CCA ( Figure 1C) and IMT of the left CCA ( Figure 1D ) did not differ in the uncontrolled BP groups as compared with CH.
Twenty-four hour-PWV was 9.1±1.5 m/sec in men and 8.5±1.8 m/sec in women. The results of the adjusted analysis of 24-hour PWV in relation to BP pattern are given in Figure 2 . PWV averaged over 24 hours (Figure 2A ) was significantly elevated in patients with MUCH (+0.5 m/sec) and in patients with SUCH (+0.5 m/sec). This elevation was significant both during daytime ( Figure 2B ) and nighttime ( Figure 2C ).
Twenty-four hour-cAIx was 22±6% in men and 29±5% in women. Figure 3 shows the results of the adjusted analysis of 24-hour cAIx in relation to BP pattern. Twenty-four hour-cAIx ( Figure 3A ) was significantly increased in patients with MUCH (+2.5%) and SUCH (+2.9%) compared with CH. During daytime, the difference between MUCH and CH (+4.1%) and SUCH and CH (+3.8%) was even greater ( Figure 3B ). In contrast, no differences between groups were found during nighttime ( Figure 3C ).
Relationships with TOD remain consistent when defining BP patterns by office BP and daytime ambulatory BP ( Figure S1 ) or by office BP and nighttime ambulatory BP ( Figure S2 ). 
Discussion
In patients with CKD, data on BP pattern and its association with TOD are sparse. Given the expanding list of potential uremic or nontraditional risk factors, the role of BP pattern for TOD in CKD is unclear. In the current oligo-center study, we have recruited CKD patients from nephrology practices (secondary care) to reduce differences in treatment patterns and examined BP patterns and several parameters of subclinical TOD. It is important to emphasize that most of our CKD patients were on antihypertensive therapy. This is consistent with data from larger cohorts of CKD patients, such as our parent GCKD study or the United States-based CRIC (Chronic Renal Insufficiency Cohort). 11, 12 A clinically important main finding of this study is that misclassification of BP status occurs in almost one-third of patients with CKD. Moreover, patients who were misclassified because of discrepancies between office and ambulatory BP (WCUH and MUCH) had elevated parameters of cardiac and vascular TOD. The relationships with TOD were consistent whether using 24-hour ABPM, only daytime or only nighttime ABPM values for the definition of BP pattern. Of note, nighttime ABPM identified more patients with MUCH than daytime ABPM, a finding that is consistent with reports from other CKD cohorts. 13 Furthermore, nighttime BP was shown to be better than daytime BP as a predictor of CV events and renal death in CKD patients. 14 Left ventricular hypertrophy is a strong and well-established predictor of CV mortality in the general population and in patients with CKD. 15, 16 Furthermore, left ventricular hypertrophy has been linked with the increased risk of sudden cardiac death as CKD progresses. 17 In the current study, we could show that patients with WCUH and those with MUCH had increased LVM compared with patients with CH. Drawz et al 18 recently reported from the CRIC that LVM is increased in CKD patients with MUCH but not in those with WCUH. In contrast, Verberk et al 19 reported that LVM is increased in CKD patients with WCUH or MUCH.
Several studies have shown that increased IMT, as a subclinical manifestation of atherosclerosis, is associated with increased risk of CV events, although we are not aware of any data from a CKD population. The European Society of Cardiology/European Society of Hypertension guidelines recommend IMT measurement for assessment of subclinical TOD in hypertensive patients. 20 In the general population, a meta-analysis has reported that patients with MUCH have an increased IMT compared with patients with CH. 21 In our current study, we did not find a relationship between BP pattern and IMT. Previous studies suggest that age is the dominant factor for increased IMT, albeit the largest part of IMT variation seems to remain unexplained. 22 Interestingly, IMT of the left CCA was slightly larger than IMT of the right CCA. This has been reported previously also by other investigators and might be because of differences in hemodynamic factors. 23, 24 Measurement of PWV, which depends on the degree of arterial stiffening, and measurement of the magnitude of pulse wave reflection in the central aorta (cAIx), which depends on arterial stiffening, as well as on peripheral vascular structure and function, have gained tremendous interest over the past 2 decades. This interest seems justified as several studies reported that these parameters improve prediction of CV events in the general population and in patients with arterial hypertension. [25] [26] [27] The European Society of Cardiology/ European Society of Hypertension guidelines thus recommend measurement of PWV for TOD assessment in hypertensive patients. 20 Because of recent methodological improvements, PWV and cAIx can now be measured in the ambulatory setting over 24 hours. Age-and sex-specific reference values have been published for office measurements 28 but not yet for these novel 24-hour-ambulatory measurements. We found that 24-hour PWV was increased in CKD patients with MUCH and SUCH compared with patients with CH. This increase was observed when PWV was averaged over 24 hours, as well as during separate analyses of daytime and nighttime values. Interestingly, we found no difference in 24-hour PWV between CKD patients with MUCH and SUCH. In contrast, a previous study in obese subjects found that PWV was lower in those with MUCH versus those with SUCH. 29 In the CRIC, PWV has recently been shown to independently predict CKD progression and death, underscoring the relevance of this novel parameter in CKD patients. 30 Age-and sex-specific reference values have also been published for cAIx, but again, such reference values are only available for office measurements. 31 We found that 24-hour cAIx was increased in the CKD patients with MUCH and SUCH compared with CH. Interestingly, when analyzing daytime and nighttime values separately, this increase was observed only during daytime. Circadian rhythm studies suggest that cAIx is greater during active daytime, 32 which is presumably why we observed the differences during daytime, and not during nighttime.
A first small study from China demonstrated that CKD patients with MUCH experience more CV events during follow-up than CKD patients with CH. 33 Another study in 489 CKD patients reported that MUCH associates with a risk of CV events similar to that of SUCH. 34 Furthermore, a recent study from China in 588 CKD patients reported an increased risk of CV events, greater overall mortality and more rapid renal function decline in patients with MUCH compared with CH. In contrast, a smaller study from Japan in 104 CKD patients was not able to demonstrate an association between home BP values and CV outcomes. 35 However, as a caveat to that last report, reproducibility of BP categories and diagnosis of MUCH has been shown to be more precise with ABPM than with home BP measurements. 13, 36 Our study has strengths and limitations. As a particular strength, this is the first study to relate BP pattern to LVM determined by MRI. Compared with echocardiography, MRI is much more precise for cardiac structure quantification. 37 Furthermore, PWV and cAIx were for the first time in this context determined over 24 hours in the ambulatory setting. As a limitation, our sample size and the recruitment from secondary care may limit generalizability of our findings. In addition, repeat assessment of office and ambulatory BP could have improved diagnostic accuracy of BP patterns, but this was beyond the scope of the current study.
In conclusion, we could demonstrate discrepancies between office and ambulatory BP in almost one-third of patients with CKD. Patients who were misclassified had elevated parameters of cardiac and vascular TOD. While the current KDIGO guideline emphasizes that there is insufficient evidence from randomized controlled trials to recommend ABPM to evaluate BP in CKD patients, 38 our findings add to the growing indirect evidence supporting its wider use.
Perspectives
There is accumulating evidence supporting the use of ambulatory BP measurements for more accurate identification of true BP status. However, in patient with CKD, there is to date little evidence supporting this. We could demonstrate that relying on office BP measurements alone would lead to misclassification of true BP status in almost one-third of patients with CKD and that misclassification would leave patients with subclinical TOD undetected. Thus, our data add to the growing evidence to support a wider use of ambulatory BP measurements.
